Key Takeaways
- Shares of AZN declined approximately 2% in pre-market hours despite encouraging clinical trial results
- The company’s drug Tezspire successfully achieved both primary and secondary goals in advanced-stage eosinophilic esophagitis testing
- Trial participants experienced reduced esophageal inflammation and enhanced swallowing function versus placebo group
- As a currently approved asthma medication, Tezspire recorded $1.13 billion in revenue during 2025
- Analyst consensus rates AZN as a Strong Buy with a $221.40 average target price, suggesting 33% potential gains
Shares of AstraZeneca experienced a nearly 2% decline in pre-market hours Thursday, despite the pharmaceutical giant announcing successful results from a late-stage clinical trial evaluating Tezspire for treating eosinophilic esophagitis.
The medication, jointly developed with Amgen, saw both companies’ shares retreat following the announcement. Amgen’s stock similarly declined, despite the fundamentally encouraging clinical findings.
According to trial results, Tezspire successfully achieved all primary and secondary objectives. Data demonstrated that patients receiving the drug experienced decreased esophageal inflammation levels and improved ability to swallow when compared against those receiving a placebo.
This chronic inflammatory disease, known as eosinophilic esophagitis, impacts over 470,000 individuals across the United States. Patients often struggle with eating, experiencing difficulty as food progresses slowly through the esophagus or becomes lodged entirely.
The therapeutic mechanism of Tezspire involves inhibiting TSLP, a protein responsible for triggering inflammation associated with eosinophilsāa specific type of white blood cell. This identical mechanism underlies its effectiveness in treating severe asthma, the indication for which it currently holds approval.
According to AZN, approximately 50% of patients diagnosed with this condition, including younger adolescent patients, fail to achieve sufficient symptom control using existing front-line therapies. These standard treatments encompass elimination diets, topical corticosteroids, and medications that reduce stomach acid production.
Regulatory authorities in the United States, European Union, and multiple additional countries have already approved Tezspire as an adjunctive therapy for severe asthma. The medication generated $1.13 billion in revenue for AstraZeneca throughout 2025.
Pipeline Challenges Continue for AZN
These encouraging Tezspire results arrive following multiple developmental disappointments for AstraZeneca during 2026. Last July, Wainuaāa collaborative project with Ionis Pharmaceuticalsāsurprisingly missed its endpoints in testing for transthyretin amyloid cardiomyopathy, a potentially fatal cardiac condition.
Another late-phase trial evaluating the rare disease therapy Ultomiris similarly fell short of expectations. Earlier in May, a United States advisory committee voted against approving camizestrant for breast cancer treatment, citing concerns regarding the clinical trial structure.
Most recently this month, the company discontinued a clinical study examining volrustomig for lung cancer after determining the trial would probably not achieve its predetermined objectives.
Year-to-date performance shows AZN shares declining 3.63% entering Thursday’s trading session.
Wall Street’s Perspective
Notwithstanding these developmental challenges, the investment community maintains an optimistic outlook. TipRanks data shows AZN carrying a Strong Buy consensus rating, comprising 12 Buy recommendations, 1 Hold, and 1 Sell.
The average analyst price target stands at $221.40, indicating potential upside of 33% from present trading levels. The most bullish forecast reaches $275.35.
The successful esophagitis trial outcome may bolster Tezspire’s market prospects, particularly considering the medication already surpassed $1 billion in asthma-related sales during 2025.
AstraZeneca has yet to disclose when it plans to submit these new trial findings to regulatory authorities for approval consideration.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
